Oncological diseases. Inflammatory forms of disease (e.g. fever of unclear origin, vasculitis, spondylodiscitis or unclear inflammation in the chest / pulmonary etc.) C15.9 C43 C83 C14 C32 C80 C19 C53 C54 C85 I77
Conditions
Interventions
Group 1: Patients with oncological or inflammatory disease who, due to the study, also acquire dynamic PET data in addition to their clinically indicated PET/CT or PET/MRT in static recording mode.
Th
Sponsors
Universitätsklinikum Tübingen, Radiologische Klinik, Nuklearmedizin & Klinische Molekulare Bildgebung
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: • Clinical indication for a PET/CT or PET/MRI examination • Patients with a malignant or inflammatory disease • Patients who are able to understand the nature and scope of the pseudonymized, prospective data collection • Patients who tolerate 80 min measuring time in the PET/CT scanner • Age =18 years • Written consent of the patient
Exclusion criteria
Exclusion criteria: • Pregnant and lactating women, • Patients with claustrophobia, • Patients with problems/pain when lying on their back, who may not tolerate a measurement time of more than one hour, • Exclusion criteria according to the Radiation Protection Ordinance (StrlSchV), • The patient's limited ability to consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary goal of this study is to collect dynamic PET parameters (Ki, DV, K1 and Vb) from the primary tumor, lymph node regions, distant metastases, inflammatory tissues and reference organs and to correlate them with clinically indicated follow-up examinations or histopathological analyzes (“gold standard”). | — |
Secondary
| Measure | Time frame |
|---|---|
| • Differentiation of inflammatory and tumor-associated tissue changes using suitable dynamic PET parameters, • Investigation of of PET tracer kinetics in tumorous, inflammatory and healthy tissue and organs, • Correlation of dynamic parameters with semi-quantitative measurements of static images, • Assessment of the response of chemotherapy, immunotherapy and modulators, radiotherapy and radio peptide therapies, • Optimization of the workflow for dynamic wb-PET/CT or PET/MRI and shortened dynamic whole body imaging, • Shortening of the dynamic examination protocol by correlation with the activity from venous blood samples. | — |
Countries
Germany
Contacts
Public ContactMatthias Weissinger
Universitätsklinikum Tübingen, Radiologische Klinik, Nuklearmedizin & Klinische Molekulare Bildgebung
Outcome results
None listed